SCHEMBL6480301

SCHEMBL6480301

Cc1cc2cc(NC(=O)C3CCC(=O)C3)ccc2n1C(=O)c1cc(Cl)nc(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.44
PARP15 Q460N3 1/20 0.44
PARP10 Q53GL7 1/20 0.44
AKR1C3 P42330 1/20 0.38
AKR1C2 P52895 1/20 0.38
MAPT P10636 1/20 0.37
UBE2M P61081 1/20 0.37
DCUN1D1 Q96GG9 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
TUBB1 Q9H4B7 1/20 0.35
ALDH1A1 P00352 1/20 0.35
RAB9A P51151 1/20 0.35
HPGD P15428 1/20 0.35
NPC1 O15118 1/20 0.35
MALT1 Q9UDY8 2/20 0.34
KDM4E B2RXH2 2/20 0.34
USP2 O75604 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6227961 0.89 UBE2M (0.43) AKR1C3AKR1C2MAPTUBE2MDCUN1D1
SCHEMBL6492249 0.83 PARP1 (0.48) PARP1PARP15PARP10MAPTUBE2M
SCHEMBL6493472 0.82 PARP1 (0.44) PARP1PARP15PARP10MAPTL3MBTL1
SCHEMBL6494500 0.80 PARP1 (0.45) PARP1PARP15PARP10TUBB1ALDH1A1
SCHEMBL6480758 0.76 PARP1 (0.42) PARP1PARP15PARP10MAPTUBE2M
SCHEMBL6487994 0.74 MEN1 (0.46) MAPTUBE2MDCUN1D1HPGDMALT1
SCHEMBL6480891 0.72 NPSR1 (0.50) UBE2MDCUN1D1ALDH1A1HPGDUSP2
SCHEMBL6492262 0.72 NPSR1 (0.47) UBE2MDCUN1D1ALDH1A1HPGDMAOA
SCHEMBL6490763 0.72 GRM4 (0.53) UBE2MDCUN1D1ALDH1A1HPGDUSP2
SCHEMBL6481059 0.71 NPSR1 (0.49) ALDH1A1HPGDKDM4EUSP2MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050215614-A1 Substituted indoles and their use as hcv inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215614-A1 Substituted indoles and their use as hcv inhibitors IDO1, IDO2, HAVCR2 PARP1 3678/4885PARP15 2460/4885PARP10 2475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.